List of works - IÑAKI COMINO-MENDEZ

ATRX driver mutation in a composite malignant pheochromocytoma

scientific article

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer

scientific article published on 01 August 2019

Challenges and achievements of liquid biopsy technologies employed in early breast cancer

scientific article published on 05 November 2020

DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers

scientific article published on 30 March 2015

Detection of the first gross CDC73 germline deletion in an HPT-JT syndrome family.

scientific article

Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma

scientific article (publication date: 19 June 2011)

Functional and in silico assessment of MAX variants of unknown significance

scientific article

Gain-of-function mutations in DNMT3A in patients with paraganglioma

scientific article published on 08 May 2018

Hematologic β-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity.

scientific article

Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways

scientific article published on 24 June 2013

MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma

scientific article published on 27 March 2012

Predicting Relapse with Circulating Tumor DNA Analysis in Lung Cancer

scientific article published in December 2017

Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.

scientific article published on 12 August 2015

Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy.

scientific article published on 20 June 2012

Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients

scientific article published on 16 July 2018

Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer-Predisposing Mutations in Pheochromocytomas and Paragangliomas.

scientific article published on 18 July 2017

Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis

scientific article published on 14 February 2013

VEGF, VEGFR3, and PDGFRB protein expression is influenced by RAS mutations in medullary thyroid carcinoma.

scientific article

Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene.

scientific article

List of works by IÑAKI COMINO-MENDEZ

ATRX driver mutation in a composite malignant pheochromocytoma

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer

Challenges and achievements of liquid biopsy technologies employed in early breast cancer

DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers

Detection of the first gross CDC73 germline deletion in an HPT-JT syndrome family.

Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma

Functional and in silico assessment of MAX variants of unknown significance

Gain-of-function mutations in DNMT3A in patients with paraganglioma

Hematologic β-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity.

Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways

MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma

Predicting Relapse with Circulating Tumor DNA Analysis in Lung Cancer

Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.

Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy.

Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients

Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer-Predisposing Mutations in Pheochromocytomas and Paragangliomas.

Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis

VEGF, VEGFR3, and PDGFRB protein expression is influenced by RAS mutations in medullary thyroid carcinoma.

Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene.